Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Other Operating Expenses (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Other Operating Expenses for 16 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 10.32% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $71.8 million through Dec 2025, up 151.73% year-over-year, with the annual reading at $71.9 million for FY2025, 147.35% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $6.2 million at Harvard Bioscience, up from $5.5 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $54.3 million in Q1 2025, with the low at $5.5 million in Q3 2025.
  • Average Other Operating Expenses over 5 years is $9.6 million, with a median of $7.4 million recorded in 2022.
  • Peak annual rise in Other Operating Expenses hit 561.38% in 2025, while the deepest fall reached 20.2% in 2025.
  • Over 5 years, Other Operating Expenses stood at $8.5 million in 2021, then dropped by 10.79% to $7.6 million in 2022, then increased by 0.69% to $7.6 million in 2023, then fell by 9.97% to $6.9 million in 2024, then dropped by 10.32% to $6.2 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $6.2 million, $5.5 million, and $5.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.